Allogene Therapeutics Q3 EPS $(0.15), Inline
Benzinga Newsdesk 9 hours ago
NewsEarnings
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 21.05 percent increase over losses of $(0.19) per share from the same period last
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 21.05 percent increase over losses of $(0.19) per share from the same period last year.